Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma.

Pei-Chang LeeYee ChaoMing-Huang ChenKeng-Hsin LanI-Cheng LeeMing-Chih Hou Yi-Hsiang Huang

Published in: Journal for immunotherapy of cancer (2021)

No patients on antiviral therapy developed HBV reactivation, and one out of six not receiving antiviral therapy had HBV reactivation. HBV viral load higher than 100 IU/mL is safe and not a contraindication for ICI treatment for HCC, if NUCs can be coadministrated.

Keyphrases

hepatitis b virus
liver failure
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
squamous cell carcinoma
radiation therapy
locally advanced
rectal cancer
cell therapy
patient reported